Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-Paclitaxel and Gemcitabine in Recurrent/Refractory Sarcoma in Teenagers and Young Adults
NCT02945800Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2016
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in osteosarcoma (OS), Ewing sarcoma, rhabdomyosarcoma (RMS) and 1 more, sponsored by Moffitt Cancer Center. Primary endpoints: Response Rate at 13 months and Progression Free Survival at 13 months. Started Oct 2016; status: completed.
02
Drugs
paclitaxel
03
Conditions
osteosarcoma (OS)Ewing sarcomarhabdomyosarcoma (RMS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02945800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02945800.